Literature DB >> 3338269

C4-binding protein prevents spontaneous cleavage of C3 in sera of patients with hereditary angioedema.

P Gronski1, L Bodenbender, E J Kanzy, F R Seiler.   

Abstract

We have studied the effects of polyclonal monospecific Fab' preparations against C1r, C1s, C1INH, C4, C4bp, and fragment Bb of factor B on complement activation in NHS and HAES. Furthermore, we have investigated complement activation in these sera after addition of purified C1s and purified C4bp. Blocking C1INH induced a spontaneous activation of the classical pathway in NHS and to a lesser extent in HAES. Addition of p-C1s resulted in a strong C3 conversion in NHS, but not in HAES. However, after the blocking of C4bp in HAES, addition of p-C1s produced a total C3 consumption. The ration of the protein concentration of C4bp to hemolytically active C4 was eight times higher in HAES than in NHS. This increased ratio may account for the resistance of HAES to the C1s induced C3 cleavage in our in vitro system and the stability of C3 in HAE despite C4 and C2 consumption in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338269     DOI: 10.1159/000463026

Source DB:  PubMed          Journal:  Complement        ISSN: 0253-5076


  3 in total

1.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  Depressed activation of the lectin pathway of complement in hereditary angioedema.

Authors:  L Varga; G Széplaki; J Laki; A Kocsis; K Kristóf; P Gál; Z Bajtay; J Wieslander; M R Daha; P Garred; H O Madsen; G Füst; H Farkas
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

3.  Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathway.

Authors:  L Bergamaschini; A Miedico; M Cicardi; R Coppola; E N Faioni; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.